Project Grant K99CA304214
Award Date
7/14/25
Completion Date
6/30/27
Dollars Obligated
$136K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $514,196 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The grant, which runs from September 1, 2024 to April 2, 2027, will support research to investigate IGF2BP1 as a novel therapeutic target for Ewing sarcoma, the second most prevalent bone cancer among children. The project aims to validate IGF2BP1 as an Ewing sarcoma dependency, determine the molecular...
This federal Project Grant award of $216,972 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to understand and target vulnerabilities governing the G1/S transition and replication stress in small cell lung cancer (SCLC). The key objectives are to: 1) determine the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA levels and R-loops, and develop therapeutic approaches targeting...
This Project Grant award of $230,010 from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to unravel the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The award was granted to the University of Chicago and will run from March 1, 2025 to February 28, 2027. The research integrates human pluripotent stem cell-derived SCLC models, clinical samples, and patient-derived...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The $172,193 grant, awarded on May 7, 2025, supports a 5-year research project to characterize gene regulatory elements and metabolic functions in a rare and aggressive form of renal cell carcinoma known as translocation renal cell carcinoma (TRCC). The research aims to develop optimization methods to...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...
The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
This $703,410 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University (NYU) School of Medicine to investigate molecular mechanisms underlying the transition from lung adenocarcinoma to squamous cell carcinoma, which can contribute to resistance to KRAS inhibitor therapies. The research aims to identify chromatin regulators that drive this lineage transition, and systematically decouple the...
This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675.00 to The University of Texas Southwestern Medical Center to conduct research on innovative therapeutic strategies for small cell lung cancer (SCLC). The research aims to investigate the role of Jumonji demethylases as potential druggable targets in SCLC, including evaluating the impact of Jumonji inhibitors on SCLC growth and therapeutic resistance. The project will...